We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
+5.71%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$273M
AUM Growth
-$40.2M
Cap. Flow
-$46M
Cap. Flow %
-16.86%
Top 10 Hldgs %
90.67%
Holding
21
New
–
Increased
–
Reduced
5
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
ARQT icon
Arcutis Biotherapeutics
ARQT
+$13.3M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$11.5M
3
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$11.5M
4
REPL icon
Replimune Group
REPL
+$7.35M
5
IMCR icon
Immunocore
IMCR
+$1.92M

Sector Composition

Rank Sector Weight
1 Healthcare 98.18%
2 Financials 1.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REPL icon
1
Replimune Group
REPL
$814M
$74.1M 27.12%
4,288,154
-385,226
-8% -$7.35M
IMGO
2
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
$45.4M 16.64%
3,018,737
– –
NUVB icon
3
Nuvation Bio
NUVB
$2.24B
$33.8M 12.36%
15,072,340
-175,000
-1% -$500K
CINC
4
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$18.4M 6.74%
560,985
-405,191
-42% -$11.5M
GOSS icon
5
Gossamer Bio
GOSS
$66.5M
$18M 6.58%
1,500,000
– –
MORF
6
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$16.9M 6.19%
597,723
-413,046
-41% -$11.5M
ALPN
7
DELISTED
Alpine Immune Sciences Inc
ALPN
$14.6M 5.35%
2,029,580
– –
KRON
8
DELISTED
Kronos Bio
KRON
$12.8M 4.68%
3,818,283
– –
IMA
9
ImageneBio Inc
IMA
$63.1M
$7.98M 2.92%
187,427
– –
IMUX icon
10
Immunic
IMUX
$182M
$5.65M 2.07%
178,816
– –
PRTK
11
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$5.07M 1.86%
1,971,241
– –
SANA icon
12
Sana Biotechnology
SANA
$885M
$5.06M 1.85%
843,750
– –
OMEG
13
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$4.97M 1.82%
501,000
– –
THRX
14
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$4.13M 1.51%
711,479
– –
SPRB
15
Spruce Biosciences
SPRB
$119M
$2.96M 1.08%
28,814
– –
SYRS
16
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.62M 0.59%
251,270
-1
-0% -$8
JNCE
17
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$645K 0.24%
275,513
– –
EPIX
18
DELISTED
ESSA Pharma
EPIX
$597K 0.22%
328,196
– –
SNTI icon
19
Senti Biosciences Holdings
SNTI
$12.6M
$425K 0.16%
19,579
– –
ARQT icon
20
Arcutis Biotherapeutics
ARQT
$3.42B
– –
-623,836
Closed -$13.3M
IMCR icon
21
Immunocore
IMCR
$1.78B
– –
-51,535
Closed -$1.92M

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q3 2022 Portfolio in Review

As of Q3 2022, Omega Fund Management held 21 positions worth $273M, down 13% from $313M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Omega Fund Management withdrew a net $46M in Q3 2022, closing 2 positions and reducing 5 holdings. Its most notable exit was Arcutis Biotherapeutics, an estimated $13.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Financials.

  • Omega Fund Management's biggest Q3 2022 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $11.5M.
  • Omega Fund Management fully exited Arcutis Biotherapeutics in Q3 2022, selling an estimated $13.3M.
  • Omega Fund Management's ten largest holdings make up 91% of its $273M portfolio in Q3 2022.
  • Omega Fund Management opened 0 new positions and closed 2 in Q3 2022.
  • Omega Fund Management's portfolio value fell 13% quarter-over-quarter to $273M.

Based on Omega Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.